General discussion, page-4011

further along in that running set of comments in regard to the article you posted, the good Dr S made some very salient points about Cannvalates' expertise in the same area..

Cannvalate’s Medicinal Cannabis Research Collaboration has been a global leader in the cannabinoid research space for > 2 years.

An exciting time for scientists and physician researchers.
With expertise in:
Orphan Drug development
FDA505(b)2 applications
Schedule 3 CBD development
Novel cannabinoid development
Early stage POC clinical trials
IND-enabling studies

Another reason to underpin the view IHL will have success - the experience / expertise crossover is an (up to this point) unrecognised value add of major significance imo, both in the pending IND application and in the ongoing drug development research that we are all so aware of.

again, the Jazz / GW development underpins the IHL approach and the commensurate dollar value to attach? well, when the market catches on.....we'll soon see imo

20c fast approaching...just as quickly roadkill imo
GLA